WO2009035534A3 - Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif) - Google Patents
Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif) Download PDFInfo
- Publication number
- WO2009035534A3 WO2009035534A3 PCT/US2008/010413 US2008010413W WO2009035534A3 WO 2009035534 A3 WO2009035534 A3 WO 2009035534A3 US 2008010413 W US2008010413 W US 2008010413W WO 2009035534 A3 WO2009035534 A3 WO 2009035534A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hif
- eye disease
- systematic
- treatment
- inducible factor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Abstract
The present invention consists of a method of treating a subject with an ischemic eye disease associated with the down-regulation of HIF comprising administering to the subject an effective amount of a compound that induces HIF activity and/or induces EPO activity to induce and maintain growth or normal retinal blood vessels in the early stage of the disease.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96790107P | 2007-09-07 | 2007-09-07 | |
US60/967,901 | 2007-09-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009035534A2 WO2009035534A2 (en) | 2009-03-19 |
WO2009035534A3 true WO2009035534A3 (en) | 2009-05-07 |
Family
ID=40134829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/010413 WO2009035534A2 (en) | 2007-09-07 | 2008-09-05 | Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif) |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009035534A2 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104945318A (en) | 2010-06-01 | 2015-09-30 | 拜欧赛里克斯公司 | Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases |
EP2688569B1 (en) * | 2011-03-21 | 2018-05-30 | Vivolux Ab | Treatment of solid tumours |
NO2686520T3 (en) | 2011-06-06 | 2018-03-17 | ||
EP2900667B1 (en) | 2012-09-21 | 2019-06-05 | Vivolux AB | Means and method for treating solid tumours |
LT3007695T (en) | 2013-06-13 | 2024-03-25 | Akebia Therapeutics, Inc. | Compositions and methods for treating anemia |
CA2937349A1 (en) * | 2014-01-23 | 2015-07-30 | Akebia Therapeutics, Inc. | Compositions and methods for treating ocular diseases |
TW201632504A (en) | 2015-01-23 | 2016-09-16 | 阿克比治療有限公司 | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
CR20170450A (en) | 2015-04-01 | 2018-04-03 | Akebia Therapeutics Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF THE ANEMIA |
AU2016371541B2 (en) * | 2015-12-18 | 2021-07-08 | Vivolux Ab | Pharmaceutical composition comprising indole derivatives, process for preparation and use thereof |
GB201720320D0 (en) * | 2017-12-06 | 2018-01-17 | Univ Of Sussex | Tissue repair |
WO2019136466A1 (en) | 2018-01-08 | 2019-07-11 | Yale University | Compounds and methods for treating or preventing anterior segment ocular disorders and/or retinal degenerations |
CA3097219A1 (en) | 2018-05-09 | 2019-11-14 | Akebia Therapeutics, Inc. | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
JP2023532134A (en) * | 2020-07-02 | 2023-07-26 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Cyclic compound for use in treating retinal degeneration |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002089809A1 (en) * | 2001-05-04 | 2002-11-14 | The Procter & Gamble Company | Medicinal uses of hydrazones and hydrazines |
-
2008
- 2008-09-05 WO PCT/US2008/010413 patent/WO2009035534A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002089809A1 (en) * | 2001-05-04 | 2002-11-14 | The Procter & Gamble Company | Medicinal uses of hydrazones and hydrazines |
US20030092716A1 (en) * | 2001-05-04 | 2003-05-15 | The Procter & Gamble Company | Medicinal uses of hydrazones |
Non-Patent Citations (4)
Title |
---|
JUNK A K ET AL: "Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, vol. 99, no. 16, 1 January 2002 (2002-01-01), pages 10659 - 10664, XP008090830, ISSN: 0027-8424 * |
NAGLE DALE G ET AL: "Natural product-derived small molecule activators of hypoxia-inducible factor-1 (HIF-1).", CURRENT PHARMACEUTICAL DESIGN 2006, vol. 12, no. 21, 2006, pages 2673 - 2688, XP002509125, ISSN: 1381-6128 * |
WHITLOCK N ANDREW ET AL: "Hsp27 upregulation by HIF-1 signaling offers protection against retinal ischemia in rats.", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE MAR 2005, vol. 46, no. 3, March 2005 (2005-03-01), pages 1092 - 1098, XP002509127, ISSN: 0146-0404 * |
ZHU Y ET AL: "DESFERROXAMINE PRETREATMENT PROMOTES PROLONGED RETINAL ISCHEMIC TOLERANCE IN MICE: A NEW MODEL OF CHEMICAL PRECONDITIONING IN RETINA", ARVO ANNUAL MEETING ABSTRACT SEARCH AND PROGRAM PLANNER, vol. 2003, 2003, & ANNUAL MEETING OF THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY; FORT LAUDERDALE, FL, USA; MAY 04-08, 2003, pages Abstract No. 2925, XP002509126 * |
Also Published As
Publication number | Publication date |
---|---|
WO2009035534A2 (en) | 2009-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009035534A3 (en) | Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif) | |
PH12018500767A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
EA201300522A1 (en) | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS | |
WO2007120936A3 (en) | Use.of vildagliptin for the treatment of diabetes | |
WO2011020319A8 (en) | Fusion protein regulating plasma glucose and lipid, its preparation method and use | |
PH12015501009A1 (en) | A composition for treating diabetes or diabesity comprising oxyntomodulin analog | |
WO2009055331A3 (en) | Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119 | |
WO2005107730A3 (en) | Cysteamines for treating complications of hypercholesterolemia and diabetes | |
EA200900896A1 (en) | HETEROCYCLIC COMPOUND RECEPTOR-AGONISTS (VARIANTS) PHARMACEUTICAL COMPOSITION ON THEIR BASIS METHOD FOR TREATING DIABETES AND METABOLIC DISORDERS, a method of stimulating insulin production (VARIANTS) AND METHODS FOR REDUCING GLUCOSE LEVEL IN BLOOD AND TRIGLYCERIDES BY COMPOUNDS LISTED | |
WO2010065671A3 (en) | Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf | |
TW200740804A (en) | Glucokinase activators | |
EA201101187A1 (en) | ANTI-DIABETIC MEDICINES CONTAINING DPP-4 INHIBITOR (LINAGLIPTIN) OPTIONAL IN COMBINATION WITH OTHER ANTI-DIABETIC MEANS | |
WO2007117381A3 (en) | 2 -aminopyridine analogs as glucokinase activators | |
EP3773880A4 (en) | Therapeutic modulation to treat blood glucose abnormalities, including type 2 diabetes, and/or reduce hba1c levels, and associated systems and methods | |
WO2008149802A1 (en) | Anti-fatigue agent and oral composition each comprising andrographolide as active ingredient | |
WO2006098603A3 (en) | Composition comprising isoorientin for suppressing histamine | |
WO2010042886A3 (en) | Pyrones for the treatment of metabolic disorders | |
WO2007056301A3 (en) | Antibody therapy for treatment of diseases associated with gluten intolerance | |
MX366496B (en) | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use. | |
EP3590338A3 (en) | Medical treatments based on anamorelin | |
EA200800338A1 (en) | PREVENTION AND TREATMENT OF OPHTHALMOLOGICAL COMPLICATIONS OF DIABETES | |
WO2006004696A3 (en) | Compositions and methods for the prevention and control of insulin-induced hypoglycemia | |
WO2007005774A3 (en) | Novel derivatives of amino acids for treatment of obesity and related disorders | |
WO2007076505A3 (en) | Transferrin and transferrin-based compositions for diabetes treatment | |
WO2006020912A3 (en) | Treatments for congestive heart failure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08831068 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08831068 Country of ref document: EP Kind code of ref document: A2 |